Measurement of Low Molecular Weight Heparin Ex Vivo Activities in Clinical Laboratories Using Various Anti-Xa Assays: Interlaboratory Variability and Requirement for an Agreed Low Molecular Weight Heparin Standard

Summary

The only sensitive and convenient assay to assess the biological activity of low molecular weight heparins (LMWHs) is based on the potentiation of activated factor Xa inhibition. Several procedures for measuring the socalled anti Xa activity have been proposed. In this collaborative study including eight laboratories, we have used four different assays (three amidolytic and one clotting based methods) for measuring the anti Xa activity of ex vivo samples obtained after injecting three different LMWHs. The dispersion of the results obtained by calibration against standard heparin could be reduced by using any of the three LMWHs for calibration. A coefficient of variation less than 0.20 between values obtained in different laboratories using a variety of methods seems acceptable. However it is necessary to refer to a common international standard for expressing the results in units and to define, for each of the three products, the therapeutic range.

Keywords

Ex vivo anti-Xa activity - LMW heparins

• References

• 1 Kakkar VV, Murray W JG. Efficacy and safety of low-molecular- weight heparin (CY 216) in pieventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
• 2 Turpie A GG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. New Engl J Med 1986; 315: 925-929
• 3 Schmitz-Huebner U, Riischemeyer C, Schulte H, Van de Loo J. Influence of low molecular weight heparin on the hemostatic system after abdominal surgery. Thromb Haemostas 1985; 53: 297-300
• 4 Massonet-Castel S, Pelissier E, Dreyfus G, Deloche A, Abry B, Guibourt P, Terrier E, Passelecq J, Jaulmes B, Carpentier A. Low molecular weight heparin in extracorporeal circulation. Lancet 1984; 1: 1182-1183
• 5 Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas 1985; 54: 813-817
• 6 Huet Y, Gouhault-Heilmann M, Brun-Buisson G, Contant G, Brun-Ney D. Low molecular weight heparin fractions as anticoagulant therapy in pulmonary embolism in man. Circulation 1984; 70: 96
• 7 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahle M, Haugen K, Loerum F, Schell B, Sortland O, Vinge B. Subcutaneous heparin treatment of deep venous thrombosis: comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 suppl. (02) 30-37
• 8 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
• 9 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 10 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 11 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-679
• 12 Teien A, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
• 13 Denson K WE, Bonnar J. The measurement of heparin: a method based on the potentiation of anti-factor Xa. Thromb Diath Haemorrh 1973; 30: 471-479
• 14 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl V. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 15 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assavs of plasma heparin. Br J Haemorrh 1973; 30: 471-479
• 16 Barrowcliffe TW, Curtis AD, Thomas DP. Establishment of a low molecular weight heparin standard: Report of the international collaborative study. To be published